Novavax, Inc. (NVAX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Novavax, Inc. (NVAX) closed at USD 12.64 on 2026-10-14, a change of +48.4 % over the past year, with a market capitalization of USD 2.11B.

Novavax, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Novavax, Inc. key figures

Previous close

USD 12.64 (2026-10-14)

1-year change

+48.4 %

Market cap

USD 2.11B

Enterprise value

USD 1.69B

P/E ratio (trailing)

-8.11

P/E ratio (forward)

-78.21

EPS (trailing)

-1.58

EPS (forward)

-0.16

PEG ratio

1.32

Price to book

-11.08

Revenue growth

-76.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.08

Employees

749

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Novavax, Inc.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Novavax, Inc. and compare it with other stocks.